Seven Dragonfly-developed drugs are in clinical trials;
four wholly owned drugs will be in Phase 2 by Q2 2025
DRAGONFLY's mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes
We build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation, neurology, and beyond.
In collaboration with AbbVie, BMS, Gilead and Merck, our novel TriNKET® and CYTOKINE platforms have generated 11 Drug Candidates that have been handed off to partners.
Engaging the Immune
System to Fight Disease
Dragonfly
Latest News
The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug to enter into clinical trials.
Our Platform
TriNKET®
CYTOKINE
Two Proprietary Platforms
DRAGONFLY is a clinical-stage biotech that has developed a deep portfolio of drugs in autoimmune disease and oncology, built on two unique platforms: first-in-class tri-specific immune engagers (“TriNKET®s”) and best-in-class CYTOKINEs – each with lead drugs in the clinic with encouraging results.
Growing the
Pipeline for Patients
In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing 30+ TriNKETs® and multiple CYTOKINES across a broad range of fields, including autoimmune and inflammatory diseases, fibrosis, neurology, infectious disease, and oncology.
DRAGONFLY's pipeline is rapidly growing in a number of
therapeutic areas of critical patient need.
